Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Longitudinal Biomarker Study of Acquired Resistance and Immune Response to Palbociclib in Breast Cancer

NCT03401359 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03401359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03401359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Longitudinal Biomarker Study of Acquired Resistance and Immune Response to Palbociclib in Breast Cancer
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
October 24, 2017
Completion date
October 31, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv